Pharmacological management of obesity: an endocrine Society clinical practice guideline.
By C. Apovian, L. Aronne, D. Bessesen, M. McDonnell, M. Murad, U. Pagotto, D. Ryan, C. Still. Journal of Clinical Endocrinology and Metabolism, 2015
1,172 citations recorded by the source corpus.
OBJECTIVE To formulate clinical practice guidelines for the pharmacological management of obesity. PARTICIPANTS An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society. EVIDENCE This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. CONSENSUS PROCESS One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the European Society of Endocrinology, and The Obesity Society reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize some of the supporting evidence. CONCLUSIONS Weight loss is a pathway to health improvement for patients with obesity-associated risk factors and comorbidities. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone. Many medications commonly prescribed for diabetes, depression, and other chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight profiles, can aid in the prevention and management of obesity and thus improve health.
Subfields: Endocrinology, Diabetes and Metabolism, Pharmacology, Surgery
View Paper: https://www.semanticscholar.org/paper/32e063efbad03793d5b9794138fe9a8f9b3a4650
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022, positive): “In people with obesity, pharmacotherapy is indicated as an adjunct to lifestyle intervention for chronic weight management and can help with achieving and maintaining weight loss.(2,11,12) Long-term obesity pharmacotherapy may be required for weight maintenance, as cessation of pharmacological treat”